Tag Archives: dilated cardiomyopathy
The aptamer BC007: for the treatment of “functional autoantibody diseases”. First developed for patients with dilated cardiomyopathy
Autoimmunity is accepted as the origin or amplifier of various diseases. In the mid-1970s, a new class of “so-called” functional autoantibodies that bind to G-protein-coupled receptors (GPCR-AABs) was identified for downstream pathologies. The related “functional autoantibody diseases”
Characteristics of children with familial and idiopathic dilated cardiomyopathy
Dilated Cardiomyopathy (DCM) is a disease characterized by weakening of the heart muscle that becomes dilated and unable to pump blood efficiently. DCM is diagnosed in 0.57 of 100,000 children per year in North America and has
